Gilead Expands 340B Reporting to Wholly Owned Contract Pharmacies

Gilead exterior office sign
Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies wholly owned by covered entities.
Drugmaker Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

J&J Offers Refunds on Blockbuster Drug, Other Manufacturers Update NDCs

Johnson & Johnson building-mounted sign
Johnson & Johnson has ended its contract pharmacy restrictions for Arkansas covered entities.
Drugmaker Johnson & Johnson will offer refunds to 340B providers related to the purchases of four of its drugs, including [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

2023 Contract Pharmacy Developments: Surging Restrictions, State Law Legal Battles

In 2023, Arkansas became the first state to move to enforce a 340B contract pharmacy law as manufacturer restrictions continued to increase.
In 2023, the battle over the use of contract pharmacy arrangements by 340B providers was marked by increasing drugmaker restrictions, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Louisiana, Health Centers Seek Dismissal of Contract Pharmacy Law Challenge

AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts

Lilly
Eli Lilly is conducting government approved 340B provider audits that for the first time look for certain Medicaid health plan duplicate discounts.
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions

Takeda 340B
Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.
Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Legislation ‘Is Coming’ to Address Contract Pharmacy Restrictions, Hospital Advocate Says

Maureen Testoni headshot
Maureen Testoni, president and CEO of 340B Health, said she anticipates bipartisan legislation on drugmaker 340B contract pharmacy restrictions.
Months after it was expected, bipartisan legislation to prevent drugmaker restrictions on the use of contract pharmacies by 340B providers [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Missouri State Senator to Reintroduce 340B Contract Pharmacy, PBM Protection Bill

The Missouri state senate recently passed a 340B contract pharmacy access bill.
A Missouri state senator has filed to reintroduce a bill that would bar drugmaker 340B contract pharmacy restrictions and pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drugmakers Highlight 340B Developments in Earnings Calls

Jean-Jacques Bienaime, CEO of drugmaker BioMarin, discussed the impact of 340B on pharmaceutical sales during an investor earnings call.
Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live